Newsletter, page-19

Goooood question Chook, I'll listen out for it  
You may wish to draw attention to the statements in annual reports about the company's mission of creating share holder wealth.

Re current recruitment:

Jev - potentially the thing that is now the road block is the recruitment of the final patients.
From the 2015 restructure news item:

" The completion of enrolment and the delivery of initial results for the Phase 2 proof
of concept with the TPM®/Oxycodone patch"

Reading both the July and September 2013 shareholder newsletters they state:

"The Company expects this Phase 2 trial to be conducted in the first half of 2014."

"The first is likely to be for postherpetic neuralgia. We would expect to commence this study towards the end of the first quarter 2014. The second Phase 2 is likely to be for osteoarthritis and we are aiming
for a mid-year start"

You can throw up any garbage you like, the point is still the same. 2 years late and your share price  88% lower than at the time of the above statements. If you are happy citing approval dates whilst your wealth plummets......I suggest you check your math